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Abstract  
BACKGROUND:  This is a feasibility study to determine whether circulating tumour cells (CTCs) are 
detectable and suitable for molecular profiling in advanced endometrial cancer (aEC). 
 
METHOD: Between October 2012 and February 2014, 30 patients with aEC had baseline and up to 3 
follow-up samples.  CTCs and stathmin expression were evaluated using the CellSearch platform. 
EpCAM and stathmin immunohistochemistry were performed on FFPE tumour tissue. 
 
RESULTS:  18 from 30 (60%) patients had detectable CTCs during study [1 CTC (n=7), 2 (n=4), 3 (n=1), 
4 (n=2), 7 (n=1), 8 (n=1), 22 (n=1), 172 (n=1) in 7.5ml blood].  10 from 18 patients had between 50-
100% of detectable CTCs that were stathmin positive.  More CTC positive than CTC negative patients 
had non-endometrioid vs endometrioid histology, tumour size ≥5cm vs <5cm, higher stage disease 
and worse survival [Hazard Ratio 3.3, p>0.05, 95% CI 0.7-16.2].  21 tumour blocks were tested for 
EpCAM and stathmin IHC. Stathmin tumour immunostaining scores (TIS) on IHC were higher in CTC+ 
patients. 
 
CONCLUSION: CTC enumeration and molecular profiling with stathmin on the CellSearch platform is 
feasible in aEC.  Stathmin TIS on IHC, a known prognostic marker in EC, was associated with CTC 
positivity. 
 
   
Introduction   
Despite being the most common gynaecological malignancy in the developed world and 4th most 
common women’s cancer in the UK [1], endometrial cancer (EC) treatment is limited to standard 
chemotherapy with no approved molecularly targeted therapies.  Although 75% of patients present 
with surgically resectable early stage disease, those with regional and distant metastases have poor 
outcomes and limited treatment options. The currently used prognostic and predictive parameters 
that guide patient management in EC are based on historical clinicopathologic factors, without 
correlation with molecular aberrations.     
CTCs are cancer cells known to circulate in the peripheral blood of cancer patients and are not 
detected in healthy individuals [2].   As CTCs can be analysed from a simple blood draw, their use for 
prognostic and predictive purposes and to assess drug response and resistance is appealing.  Novel 
technologies also allow molecular characterisation on CTCs that could assist with treatment 
selection and identify changes in the molecular profile of an individual’s tumour over time [3-6]. 
Numerous techniques for the isolation and enumeration of CTCs have been reported, but only the 
CellSearch (Janssen) method is analytically validated and FDA approved for use for prostate, breast 
and colorectal cancers[7, 8] [9].  CellSearch relies on detection of epithelial cell adhesion molecule 
(EpCAM), which has a reported high expression in EC of 65-80% across all grades and stages [10].  As 
such, we investigated whether CTCs were present and could be enumerated in patients with 
advanced EC.  
Within the CellSearch system, there is a fourth channel in which a fluorescein-conjugated antibody 
of interest, stathmin in this study, can be analysed along with routine CTC morphological and 
staining features.  Stathmin is a cytosolic phosphoprotein and regulator of the microtubule 
cytoskeleton and cell cycle [11] and is also a highly relevant biomarker in EC [12], with 
overexpression demonstrated in between 27-57% [12].  It has prognostic significance in several 
malignancies, including EC [13-22] and there is evidence for its prognostic and predictive value for 
metastases [12, 21] and response to taxane chemotherapy [20, 23-25].  There is also evidence for 
stathmin as a surrogate marker of phosphoinositide 3-kinase (PI3K) pathway activation [19], one of 
the most commonly aberrant pathways in EC, and is associated with phosphatase and tensin 
homologue (PTEN) loss and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha 
(PIK3CA) amplification [19, 26].  Thus, longitudinal assessment of stathmin expression may further 
establish its role as a predictive marker of PI3K activation and in monitoring response to PI3K 
inhibition.   
 CTC enumeration and molecular profiling (MP), if feasible, may provide one of the first predictive 
biomarkers to monitor patients’ treatment in EC and allow for longitudinal assessment of molecular 
changes to assist with targeted therapy development. 
 
Methods 
Study Design 
Patients with histologically confirmed stage III and IV endometrioid (EEC) and non-endometrioid EC 
(NEEC) were eligible.  Patients were greater than 18 years of age and assessed at any time point of 
their treatment, including before surgery, before and after radiotherapy or before, during and after 
chemotherapy.  Exclusion criteria included prior history of another cancer within the last 5 years, 
except non-melanoma skin cancer.  CTC enumeration was performed every 3-6 months or if there 
was a change in clinical status, with up to 4 samples taken per patient.  
After local Research Ethics Committee and institutional approval, patients from University College 
London Hospitals (UCLH) and Sarah Cannon Research Institute UK (SCRI UK) participated between 
October 2012 and February 2014.  All patients provided written informed consent.   
For patients whose archival tumour tissue was held at UCLH histopathology department, EpCAM and 
stathmin immunohistochemistry (IHC) was performed.  Clinical data including demographic, 
clinicopathologic information, details of treatment, disease recurrence and survival were retrieved 
from the UCLH and SCRI UK patient information systems.   
Isolation and enumeration of CTCs 
At each time point, a peripheral blood sample of up to 15 ml (2x7.5ml) for CTC isolation and 
enumeration was collected in two CellSave Preservative tubes (Cat No 7900005) and maintained at 
room temperature.  Each specimen was processed within 96 hours of being received at the UCL 
Cancer Institute by trained laboratory staff who were blinded as to the clinical status of each patient. 
Using the CellSearch CTC kit on the Celltracks Autoprep system, cells expressing EpCAM were 
immunomagnetically identified.  Cells were then fluorescently labelled with 4’6 –diamidino-2-
phenylindole (DAPI), cytokeratin 8, 18, 19-phycoerythrin (CK-PE) and CD45-allophycocyan (CD45-
APC) to identify nuclear, cytokeratin and leucocyte staining respectively. The CellTracks Analyzer II 
(Cat No 9555 RUO), a four-colour semi-automated fluorescence microscope, was then used for 
scanning and reconstruction of cellular images, which were reviewed by trained laboratory staff.  
CTCs were defined as positive for CK-PE and DAPI, negative for CD45-APC and having the correct 
morphology to be characterised as a tumour cell.   
FITC conjugated stathmin antibody (at 50µg/ml, Biorbyt catalogue number orb 14103) was used in 
the fourth channel.     
FFPE Tissue Processing and IHC assessment 
For patients who had a biopsy or surgery performed at UCLH, EpCAM (1/4 dilution; mouse anti-
human, RTU-ESA; Novocastra, Newcastle, UK) and stathmin (1/30 dilution; 3352 CellSignalling, 
Hertfordshire, UK) IHC was performed on the available FFPE tumour blocks.   
Each archival tumour block was sectioned at 3 micron thickness onto charged slides, drained and 
baked at 60°C for 60 minutes.  Unstained slides were labelled and placed for IHC staining of EpCAM 
and stathmin primary antibodies on the Leica Bond III autostainer platform, using the Bond Polymer 
Refine Detection Kit (Cat No DS9800).   
The methodology and specific protocols for each primary antibody are outlined in the 
Supplementary Material. 
The EpCAM and stathmin IHC analyses were interpreted with a consultant gynae-oncology 
histopathologist, who was blinded as to the CTC status of each patient.  A Tumour Immunostaining 
Score (TIS) was generated, as previously published for both EpCAM and stathmin [12, 27, 28].  The 
TIS is a product of a proportion score and an intensity score.  For EpCAM expression, the proportion 
score describes the estimated fraction of positively stained tumour cells (0: none; 1: <10%; 2: 10-
50%; 3: 51-80%; 4: >80%).  The intensity score represents the estimated staining intensity as 
compared with a normal FFPE control (0: no staining; 1: weak; 2: moderate; 3: strong).  The TIS 
ranges from 0-12 and is classified into 4 subgroups as follows: no expression (TIS 0), weak (TIS 1-4), 
moderate (TIS 6 and 8) and intense expression (TIS 9 and 12) [28].  The stathmin TIS is also the 
product of staining intensity, scored as per the EpCAM scoring system, and the area of tumour with 
positive staining (0: no staining, 1: <10%, 2: 10-50%, 3: >50% of tumour cells).  The range is 0-9 [12] 
with moderate/intense expression as an index ≥4/9 and absent/minimal expression as an index <4, 
with a high protein level defined as the upper quartile [27, 29], as has been previously reported [12, 
27].   
Statistical Analysis 
Statistical analysis was performed using Stata, version 12.1.  Kaplan Meier curves were generated for 
time to recurrence and overall survival.  p-values less than 0.05 were considered statistically 
significant. 
 
Results 
A total of 35 patients were enrolled, of whom 3 did not meet the required eligibility criteria and 2 
were not evaluable.  The 3 ineligible patients had pre-operative CTC assessment performed based on 
staging as locally advanced EC and were then confirmed to have synchronous stage I endometrial 
and stage III or IV ovarian/primary peritoneal cancers.  Of the 2 patients that were not evaluable, 1 
consented but did not have a further blood test for CTC collection, and the other had a sample 
collected, but the CellSearch system malfunctioned at the time of analysis.   
 CTC enumeration 
The CTC results for the remaining 30 patients included 3 with locally advanced disease and 27 with 
metastatic disease.  18 of the 30 patients (60%) were CTC positive (CTC+), all of whom had 
metastatic disease.  7 of these 18 patients (39%) were positive for 1 CTC per 7.5ml blood, 4 (22%) 
had 2 CTCs, 1 had 3 CTCs (5.6%), 2 had 4 CTCs (11%) and 1 each (5.6%) had 7 CTCs, 8 CTCs, 22 CTCs 
and 172 CTCs per 7.5ml blood. 
Differences in the clinical course at the time of CTC collection for the CTC+ and CTC- patients are 
outlined in Table 1.  At the time of first CTC collection, all CTC+ patients had either newly diagnosed 
stage IV or recurrent metastatic (RM) disease compared to the 75% (9 from 12) of CTC- patients who 
had stage IV or RM disease.  Grade 3 disease and the presence of peritoneal and liver metastases 
were also more common in CTC+ patients. 
For patients whose samples were collected after disease recurrence, average time to recurrence was 
shorter in CTC+ patients at 20.3 months (11 patients, range 9-38m) compared to 30.8 months (6 
patients, range 5-95m) in CTC- patients.  The hazard ratio (HR) for recurrence was 1.7 in favour of 
CTC- patients [p>0.05, 95% confidence interval (CI) 0.5-5.2]. 
More CTC- patients were alive at last follow-up compared to CTC+ patients.  For patients who had 
died during follow-up, more CTC+ patients were deceased within 12 months after diagnosis with 
stage IV or RM disease compared to CTC- patients.    The HR for survival was 3.3 favouring the CTC- 
patients [p>0.05, 95% CI 0.7-16.2].  The small sample size and short follow-up time limit the 
statistical analysis of these data. 
In terms of histopathologic parameters, there were more NEEC than EEC tumours [14/18 (78%) vs 
6/12 (50%)] and uterine tumours larger than 5cm [11/18 (61%) vs 6/12 (50%)] in the CTC+ patients 
compared to the CTC- patients.  There were more CTC- patients with evidence of myometrial 
invasion (MMI) greater than 50% [8/12 (67%) vs 10/18 (56%)].  Frequency of lymphovascular space 
invasion (LVSI) [6/12 (50%) vs 8/18 (44%) in CTC- vs CTC+] and cervical invasion [3/12 (25%) vs 5/18 
(28%) in CTC- vs CTC+] was similar between the two groups. 
 
CTC molecular profiling 
From the 18 patients who were CTC+, 10 patients had CTCs with stathmin expression.  Eight of these 
patients had all CTCs stain positive with stathmin while the remaining 2 patients had 2 from 4 cells 
stain positive for stathmin.  This is detailed in Table 2. 
One patient was stathmin negative.  Seven patients did not have stathmin assessed due to supply 
restrictions; 3 patients with CTC 1, 1 patient with CTC 3 and patients with CTC 7, 8 and 22.   
 Correlation of EpCAM and Stathmin IHC with CTC status 
The TIS for EpCAM and stathmin IHC was evaluated for 21 cases for which the blocks were available.  
Table 3 summarises the staining intensity of EpCAM and stathmin in the CTC+ and CTC- patient 
groups. 
Eighteen from 21 cases (86%) were EpCAM positive.  Intense EpCAM TIS was found in more CTC+ 
compared to CTC- patients [12/15 (79.9%) vs 4/6 (66%)]. 
Sixteen from 21 cases (76%) were stathmin positive.  Intense stathmin TIS were also found in more 
CTC+ patients [upper quartile stathmin TIS in 7/15 (47%) vs 1/6 (17%) CTC+ vs CTC-]. 
From the 7 patients that were CTC stathmin positive and had tissue available, all had stathmin 
overexpression on IHC, compared to 1 CTC- patient.   
 
Longitudinal CTC assessment and clinical correlation 
Details of the longitudinal CTC values for both CTC+ and CTC negative (CTC-) patients and the clinical 
correlation are detailed in Table 2. 
Of the 18 CTC+ patients, 12 were sampled pre and during first-line chemotherapy for metastatic EC 
and 1 patient had follow-up samples taken during clinical trial involvement (all marked * in Table 2).  
Of the other 5, 1 developed detectable CTCs during follow-up but did not have further treatment 
and the other 4 patients were CTC+ at baseline but died without further follow-up.   
For the 13 CTC+ patients during treatment, 8 patients demonstrated changes in their CTC counts 
over time  that were concordant with their clinical and radiological progress.  Five from the 8 
patients had positive baseline CTC counts that decreased during first-line chemotherapy and 
correlated with a partial response on imaging.  One of these patients then had a CTC rise on 3rd 
follow-up with disease progression and died. One patient was CTC+ at baseline with a further 
increase during chemotherapy and died.  One patient was CTC- with stable disease during first-line 
chemotherapy but had increased CTCs post chemotherapy with disease progression and died.  The 
clinical trial patient had disease progression pre-trial with a positive CTC value that became negative 
after one month on trial corresponding with a partial response on imaging.  The other 5 from 13 
CTC+ patients had changes in CTC counts that did not correlate with their clinical picture. 
For the 12 patients who were CTC-  at baseline and in follow-up, 7 had a clinical and/or radiological 
picture that correlated with the CTC result, 1 had a discordant picture and 4 had only a single CTC 
assessment and evaluation of concordance was limited.  This is also outlined in Table 2.   
 
 
DISCUSSION 
Our study not only demonstrates the feasibility of CTC detection in EC on the CellSearch platform 
but importantly, of CTC molecular profiling with stathmin, which has potential utility across tumour 
types as a marker of PI3K pathway activity. 
The PI3K/AKT/ mammalian target of rapamycin (mTOR) pathway is one of the most studied 
pathways in EC with aberrations including oncogenic PIK3CA mutations and PTEN loss of function.  
However, reproducible, predictive, time- and cost-efficient markers of PI3K pathway activation 
remain elusive.  The finding of stathmin overexpression in this study is a novel one and is the first 
report in EC CTCs and in CTCs in general.   The next challenge in translating stathmin into a usable 
biomarker is to correlate CTC stathmin positivity with PI3K pathway activity, to see whether CTC 
stathmin status could be used to predict response to agents targeting the PI3K/Akt/mTOR pathway.  
To this end, we assessed stathmin overexpression on FFPE tissue as this is a known prognostic 
marker in EC with evidence of predictive utility in response to taxanes.  Our finding of stathmin 
overexpression on FFPE EC was 47%, consistent with the literature reports of overexpression in 
between 27% and 57% of primary tumours [21, 30].  Interestingly, CTC positivity was associated with 
higher stathmin IHC TIS, consistent with the prognostic association of stathmin overexpression and 
the worse clinical outcome of CTC+ patients here.  Further work however is required to better define 
this relationship and may in fact be worthy of investigation across tumour types including breast and 
prostate cancer, where CTCs have already demonstrated prognostic utility and activity of the PI3K 
pathway is also well documented [31, 32]. 
CTC positivity in EC has also been demonstrated by Bogani et al [33] using the Janssen CellSearch 
platform.  They reported positive CTCs in 2 from 28 (7%) EC patients preoperatively, both having 
grade 3, stage IIIC, EEC.  They also found an association with deep MMI and lymph node positivity.  
Of note, of the patients included in this study, 18 had stage I disease, 1 had stage II, 6 had stage III 
and 3 had stage IV disease.  In contrast, we demonstrated CTC positivity in 60% of patients with 
stage IV or recurrent metastatic EC, both in EEC and NEEC.   Patients with advanced EC were selected 
here, aiming to increase the detection of patients with CTC positivity that could then be followed 
longitudinally and have molecular profiling performed. 
Furthermore, in a subset of patients receiving first-line chemotherapy for metastatic disease, we 
were able to demonstrate that longitudinal assessment of CTCs correlated with clinical outcome.  
Interestingly, there was a trend between CTC positivity and higher stage, grade 3 disease, NEEC 
histology, shorter time to recurrence and reduced survival.   
There were also patients however, whose CTC follow-up did not correlate with their clinical course 
and a number of factors in our study that did not correlate with CTC positivity, including MMI, LVSI 
and cervical invasion, all being traditional parameters currently used to guide primary treatment 
post-surgery.  This may reflect the limitations of these traditional pathologic factors in guiding 
primary treatment or limitations in CTC evaluation and our sample size.   
This study demonstrates the presence of CTCs in EC using the EpCAM based CellSearch platform as 
well as early clinical correlation patterns.  Important to the utility of the CellSearch platform is the 
presence of EpCAM and overexpression was reported in 86% of the archival FFPE tissue here, 
consistent with the published literature of moderate to intense EpCAM overexpression in 80-88% 
[10, 34] of EC specimens.  However, it is known that down-regulation of EpCAM occurs when cancers 
and CTCs undergo epithelial-mesenchymal transition (EMT) and develop a more invasive phenotype 
with metastatic potential.  In a comparison of EpCAM expression on CTCs versus FFPE tissue and 
other benign disease, EpCAM expression was demonstrated to be 10-fold lower on CTCs compared 
to primary or metastatic tissue [35].  Despite such potential limitations, an EpCAM detection system 
may still be preferred in EC, particularly with its high rate of EpCAM overexpression, though other 
techniques now warrant investigation to determine the optimum method for this cancer type and 
whether a certain platform is better for enumeration or isolation for MP.  This may include other 
EpCAM based techniques such as the Gilupi nanodetector [36], or techniques based on physical 
properties such as the ISET (isolation by size of epithelial tumour cells) system [37, 38], 
dielectrophoretic field flow fractionation (depFFF) methods [39, 40], and Imagestream (Amnis) that 
combines flow cytometry and fluorescent microscopy in a single platform [41].  In terms of CTC MP, 
although the use of an antibody within the fourth channel on the CellSearch platform is the most 
time-efficient, it only allows analysis for a single antibody per blood sample and each antibody must 
be appropriately validated for use on CTCs.  Further techniques have been described to extract CTCs 
from the CellSearch magnetic cartridge and perform further MP [3, 5, 6].    
Although the small patient number here limits statistical power, correlation of CTC stathmin 
positivity with outcomes with both chemotherapy and PI3K pathway targeted agents in EC and other 
tumours is worthy of further exploration.  The ability to detect stathmin on CTCs, the reproducibility 
of staining and evidence as a marker of PI3K activation [26] make stathmin an attractive choice of 
antibody. 
Longitudinal tissue analysis of EpCAM and PI3K alterations and mapping CTC molecular analysis 
could provide strong evidence for using CTCs and their MP as a so-called ‘liquid biopsy’ to predict 
response to standard chemotherapy and molecularly targeted agents (MTAs) for each patient.   
If validated in larger studies, longitudinal evaluation of CTCs, stathmin expression and correlation 
with treatment outcome may provide the first predictive biomarker for treatment response in EC 
and act as a surrogate marker for survival in those patients who are CTC+.  CTCs and their stathmin 
expression along with further MP could be incorporated into clinical trials that assess PI3K pathway 
targeting agents and other MTAs with the potential of better streamlining clinical trial and drug 
development.  
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TABLES 
 
Table 1: Differences in treatment and clinical course between CTC+ and CTC- patients 
 CTC- (%), n=12 CTC+ (%), n=18 
Mean age in years (range) 66 (49-83) 66 (55-79) 
Sites of metastases 
Peritoneal, LN, Liver 
 
4 (44), 7 (77), 1 (8) 
 
13 (72), 15 (83), 5 (27) 
Grade 3 disease 7 (58) 15 (83) 
Survival status with stage IV 
disease based on f/u time from 
diagnosis of metastases 
 
2 from 9 died at >12m 
      (mean 13m)  
5 alive at ≤12m f/u  
2 alive >12m f/u  
     (mean 15m f/u time) 
6 from 18 died ≤12m  
2 died >12m  
     (mean 9m for these 8 pts) 
9 alive ≤12m f/u  
1 alive >12m f/u  
     (mean 8.5m f/u time) 
LN: lymph node, RM: recurrent metastatic, pts: patients, f/u: follow-up 
 
  
Table 2: Clinical and CTC Correlation for patients with longitudinal CTC assessment: CTC positive 
(left) and CTC negative (right) 
Pt Baseline 
CTC value 
(S +) 
Longitudinal 
CTC values 
(S+) 
[number of 
collections] 
Clinical picture Pt Baseline 
CTC value 
(S +) 
Longitudinal 
CTC values 
(S+) [number 
of collections] 
Clinical picture 
Patients with concordant CTC value and clinical picture  
3,
7,
8,
17 
7 (ne) 
1 (ne) 
22 (ne) 
8 (ne) 
 Only 1 sample 
taken prior to PD & 
deceased 
4 0 0 [x3] LA disease (FIGO 
IIIB) 
DF post RT 
6* 172 (ne) 3878 (0) PD during chemo & 
deceased 
20 0 0 SD on hormonal 
treatment 
9* 2 (2) 0 
 
2 [x2] 
PR during 1stline 
chemo 
PD 4m post chemo 
& deceased 
21 0 0 SD mid 1stline 
chemo 
12
* 
0 0 
 
3 (ne) 
SD during 1stline 
chemo 
PD 4m post chemo 
& deceased 
23 0 0 [x2] Local disease 
(FIGO IB) 
DF post chemo 
& RT 
13
* 
1 (1) 0 PR during 1stline 
chemo 
29 0  LA disease (FIGO 
IIIC) 
DF mid chemo 
14 0 1 (1) PD during f/u (too 
unwell for 1stline 
chemo) 
30 0 0 SD post 1stline 
chemo 
24
* 
2 (2) 1 (1) PR during 1stline 
chemo 
33 0 0 SD mid 1stline 
chemo 
26
* 
4 (2) 1 (1) PR during 1stline 
chemo 
    
27
* 
4 (2) 0 [x2] PR during 1stline 
chemo 
    
31
* 
0 1 (1) 
0 
PD pre-clinical trial 
PR post C1 clinical 
trial 
    
Patients that did not have concordant CTC value and clinical picture 
11
* 
0 2 (2) 
 
0 [x2] 
SD post 1stline 
chemo 
SD, then PD 1m 
later & deceased 
1 0 H Pre 1stline 
chemo 
No f/u 
15
* 
0 1 (1) 
0 
SD post chemo 
PD 
2 0 - PD in brain 
22
* 
2 (2) 0 PD & deceased 19 0 0 [x2] PD 
25
* 
0 1 (ne) SD 34 0 - PD in lung 
28
* 
0 1 (ne) 
 
0 
PR at C4 1stline 
chemo 
Ongoing PR at EOT 
scan 
35 0 - Pre 1stline 
chemo 
No f/u 
S: stathmin, PD: progressive disease, LA: locally advanced, FIGO: International Federation of 
Gynaecology and Obstetrics, PR: partial response, SD: stable disease, DF: disease free  
*denotes 13 patients sample during first-line chemotherapy or clinical trial involvement 
 
Table 3: EpCAM and Stathmin IHC results relative to CTC Status 
 CTC positive; n=15 (%) CTC negative; n=6 (%) 
EpCAM TIS 
Intense 
Moderate 
Weak 
No staining 
 
12 (79.9) 
1 (6.7) 
1 (6.7) 
1 (6.7) 
 
4 (66) 
1 (17) 
1 (17) 
0 
Stathmin TIS [score] 
Upper quartile 
Intense [9] 
Moderate [ 4 or 6] 
None/Weak [<4] 
Not available 
 
7 (47) 
1 (6.7) 
11 [5, 6] (73.3 [33.3, 40]) 
1 (6.7) 
2 (13.3) 
 
1 (17) 
0 
4 [3,1] (66 [50, 16])  
1 (17) 
1 (17) 
EpCAM: epithelial cell adhesion molecule, IHC: immunohistochemistry, TIS: tumour immunostaining 
score 
  
SUPPLEMENTARY MATERIAL 
On-board dewax and rehydration were performed followed by epitope retrieval by either heat-
induced (HIER with ER2, EDTA-based, Cat No AR9961) for stathmin IHC or enzymatic digestion (with 
Enzyme 1 diluted 1/2000, Bond Enzyme Pretreatment Kit, Cat No AR9551) for EpCAM IHC.  Peroxide 
block provided in the Bond Polymer Refine Detection Kit (Cat No DS9800) was then applied followed 
by the primary antibody for 30 min or 15 min for stathmin and EpCAM respectively.  This was 
followed by a rabbit anti-mouse post primary antibody for 20 min and 8 min and goat anti-rabbit 
horseradish peroxidase conjugated polymer (components of DS9800) for 20 min and 8 min for 
stathmin and EpCAM IHC respectively.  Antigens were visualised with the substrate chromogen 3,3’-
Diaminobenzidine tetrahydrochloride (DAB, Cat No 9800) and Bond DAB Enhancer (Cat No AR9432) 
was added.  Slides were counterstained with haematoxylin (component of DS9800) and mounted.   
In addition to the standard protocol, 10% goat serum was used after stathmin antibody application 
for those slides sectioned from surgical resection samples.   
 
Table 1:  Staining Protocols for EpCAM, Stathmin and p70S6kinase 
Step EpCAM  Stathmin 
B 
 Stathmin 
S 
 P70S6 
kinase 
B/S 
 
Part 1 Time 
(min) 
Temp 
(°C) 
Time Temp Time Temp Time Temp 
Bake 60 60 60 60 60 60 60 60 
Bond dewax 
solution 
0.5 x1 
0 x1 
0 x1 
72 
72 
Room 
0.5 x1 
0 x1 
0 x1 
72 
72 
Room 
0.5 x1 
0 x1 
0 x1 
72 
72 
Room 
0.5 x1 
0 x1 
0 x1 
72 
72 
Room 
Alcohol 0 x3 Room 0 x3 Room 0 x3 Room 0 x3 Room 
BWS 0 x2 
5 x1 
Room 0 x2 
5 x1 
Room 0 x2 
5 x1 
Room 0 x2 
5 x1 
Room 
*ER2 
ER2 
ER2 
BWS 
BWS 
OR 
*Enzyme 1  
BWS 
- 
 
 
 
 
 
10 
0 x3 
- 
 
 
 
 
 
37 
Room 
0 x2 
20 
12 
0 x3 
3 
- 
Room 
100 
Room 
35 
Room 
- 
0 x2 
20 
12 
0 x3 
3 
- 
Room 
100 
Room 
35 
Room 
- 
0 x2 
30/40 
12 
0 x3 
3 
- 
Room 
100 
Room 
35 
Room 
- 
Peroxide 
block 
5 Room 5 Room  5 Room 5 Room 
BWS 0 x3 Room  0 x3 Room 0 x3 Room 0 x3 Room 
1° Ab 15 Room 30 Room 30 Room 30/60 Room 
BWS 2 x3 Room  0 x3 Room 0 x3 Room 0 x3 Room 
10% goat 
serum 
- - - - 20 Room - - 
BWS - - - - 0 x3 Room 0 x3 Room 
Post-1° Ab 8 Room 20 Room 20 Room 20 Room 
BWS 2 x3 Room  2 x3 Room 2 x3 Room 2 x3 Room 
Polymer 8 Room 20 Room 20 Room 20 Room 
BWS 2 x2 Room  2 x2 Room 2 x2 Room 2 x2 Room 
DW 0 Room  0 Room 0 Room 0 Room 
Mixed DAB 
refine 
0 & 10 Room 0 & 10 Room 0 & 10 Room 0 & 10 Room 
DW 0 x3 Room  0 x3 Room 0 x3 Room 0 x3 Room 
Bond DAB 
enhancer 
5 room 5 Room 5 Room 5 Room 
BWS 0 x3 Room  0x3 Room 0x3 Room 0x3 Room 
Haematoxylin 1 Room  1 Room  1 Room 1 Room 
DW 0 Room  0 Room  0 Room 0 Room 
BWS 0 Room  0 Room  0 Room 0 Room 
DW 0 Room  0 Room  0 Room 0 Room 
Time 0 indicates a wash, as opposed to incubation 
X3 indicates the wash occurred 3 times 
BS2: bond solution 2, BWS: bond wash solution, DW: deionised water,  
B: biopsy specimen, S: surgical resection specimen 
*This row indicates the epitope retrieval method; either with the ER2 HIER technique or enzymatic 
epitope retrieval technique with Enzyme 1. 
 
 
